Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 2
1953 1
1955 2
1956 2
1957 2
1960 1
1962 1
1963 49
1964 14
1965 10
1967 2
1968 5
1969 17
1970 65
1971 143
1972 162
1973 166
1974 166
1975 186
1976 179
1977 176
1978 188
1979 198
1980 215
1981 160
1982 163
1983 131
1984 130
1985 141
1986 135
1987 125
1988 156
1989 161
1990 184
1991 191
1992 186
1993 206
1994 180
1995 196
1996 241
1997 182
1998 222
1999 230
2000 254
2001 308
2002 304
2003 340
2004 326
2005 404
2006 394
2007 425
2008 413
2009 376
2010 416
2011 395
2012 393
2013 358
2014 367
2015 347
2016 331
2017 303
2018 303
2019 238
2020 123
Text availability
Article attribute
Article type
Publication date

Search Results

11,688 results
Results by year
Filters applied: . Clear all
Page 1
Approach to Hypertriglyceridemia in the Pediatric Population.
Valaiyapathi B, Sunil B, Ashraf AP. Valaiyapathi B, et al. Pediatr Rev. 2017 Sep;38(9):424-434. doi: 10.1542/pir.2016-0138. Pediatr Rev. 2017. PMID: 28864733 Review.
When fasting TG concentration is increased above 500 mg/dL (5.65 mmol/L), fibrates may be used to prevent pancreatitis. Omega-3 fatty acids are often used as an adjunctive therapy. ...
When fasting TG concentration is increased above 500 mg/dL (5.65 mmol/L), fibrates may be used to prevent pancreatitis. Omega-3 fatty …
Fibrates and cholestasis.
Ghonem NS, Assis DN, Boyer JL. Ghonem NS, et al. Hepatology. 2015 Aug;62(2):635-43. doi: 10.1002/hep.27744. Epub 2015 Mar 23. Hepatology. 2015. PMID: 25678132 Free PMC article. Review.
Hypertriglyceridemia: A review of the evidence.
Elkins C, Friedrich D. Elkins C, et al. Nurse Pract. 2018 Oct;43(10):22-29. doi: 10.1097/01.NPR.0000544997.22887.0b. Nurse Pract. 2018. PMID: 30153192 Review.
Benefits and risks of the treatment with fibrates--a comprehensive summary.
Okopień B, Bułdak Ł, Bołdys A. Okopień B, et al. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1099-1112. doi: 10.1080/17512433.2018.1537780. Epub 2018 Oct 23. Expert Rev Clin Pharmacol. 2018. PMID: 30328735 Review.
Furthermore, there are other clinical and biochemical benefits connected with fibrate therapy (e.g. improved insulin sensitivity). ...Here, we provide up-to-date review of benefits and potential risks associated with the therapy with fibrates. Area covered: A review …
Furthermore, there are other clinical and biochemical benefits connected with fibrate therapy (e.g. improved insulin sensitivity). .. …
Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes.
I S Sobczak A, A Blindauer C, J Stewart A. I S Sobczak A, et al. Nutrients. 2019 Aug 28;11(9):2022. doi: 10.3390/nu11092022. Nutrients. 2019. PMID: 31466350 Free PMC article. Review.
Finally, fibrates and statins, lipid-regulating drugs prescribed to subjects with T2DM, are also thought to exert part of their beneficial effects by impacting on plasma FFA concentrations. ...
Finally, fibrates and statins, lipid-regulating drugs prescribed to subjects with T2DM, are also thought to exert part of their benef …
Fibrates in the management of atherogenic dyslipidemia.
Okopień B, Buldak L, Bołdys A. Okopień B, et al. Expert Rev Cardiovasc Ther. 2017 Dec;15(12):913-921. doi: 10.1080/14779072.2017.1408410. Epub 2017 Nov 28. Expert Rev Cardiovasc Ther. 2017. PMID: 29183206 Review.
Areas covered: A review of clinical trials and experimental studies on fibrates and their use in the treatment of lipid disorders has been performed. ...Benefits of fibrate treatment extend beyond the impact of lipid profile. Significant improvements in carbohydrate …
Areas covered: A review of clinical trials and experimental studies on fibrates and their use in the treatment of lipid disorders has …
The role and regulation of the peroxisome proliferator activated receptor alpha in human liver.
Kersten S, Stienstra R. Kersten S, et al. Biochimie. 2017 May;136:75-84. doi: 10.1016/j.biochi.2016.12.019. Epub 2017 Jan 8. Biochimie. 2017. PMID: 28077274 Review.
PPARα is activated by fatty acids and various other lipid species, as well as by a class of chemicals referred to as peroxisome proliferators. ...
PPARα is activated by fatty acids and various other lipid species, as well as by a class of chemicals referred to as peroxisome proli …
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y, Shapiro MD. Handelsman Y, et al. Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7. Endocr Pract. 2017. PMID: 27819772 Review.
Fibrates, niacin, and omega-3 fatty acids (OM3FAs) are three classes of triglyceride-lowering drugs. Outcome studies with triglyceride-lowering agents have been inconsistent. ...ABBREVIATIONS: AACE = American Association of Clinical Endocrinologists ACCORD = Action
Fibrates, niacin, and omega-3 fatty acids (OM3FAs) are three classes of triglyceride-lowering drugs. Outcome studies with trig
[Presentation].
Núñez-Cortés JM. Núñez-Cortés JM. Clin Investig Arterioscler. 2016 Jul;28 Suppl 3:1-2. doi: 10.1016/S0214-9168(16)30082-1. Clin Investig Arterioscler. 2016. PMID: 27473464 Spanish. No abstract available.
Fibrates for secondary prevention of cardiovascular disease and stroke.
Wang D, Liu B, Tao W, Hao Z, Liu M. Wang D, et al. Cochrane Database Syst Rev. 2015 Oct 25;2015(10):CD009580. doi: 10.1002/14651858.CD009580.pub2. Cochrane Database Syst Rev. 2015. PMID: 26497361 Free PMC article. Review.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) in which a fibrate (for example gemfibrozil, fenofibrate) was compared with placebo or no treatment. ...The meta-analysis (including all fibrate trials) showed evidence for a protective effect of …
SELECTION CRITERIA: We included randomised controlled trials (RCTs) in which a fibrate (for example gemfibrozil, fenofibrate) was com …
11,688 results
Jump to page
Feedback